Nebulized dexamethasone sodium phosphate in the treatment of horses with severe asthma

Abstract

Abstract Background A study reported low systemic availability of injectable dexamethasone nebulized to healthy horses using the Flexineb mask. When used in horses with severe asthma and a different nebulizer, lack of efficacy and cortisol suppression were observed. Hypothesis Nebulized dexamethasone is as effective as PO administration for the treatment of severe asthma in horses. Animals Twelve horses with severe asthma from a research herd. Methods Randomized clinical trial. Horses were divided into 2 groups and received 5 mg of dexamethasone sodium phosphate by nebulization using a Flexineb mask (NE, n = 6) or PO (OR, n = 6) q24h for 7\u2009days. Lung function and serum cortisol concentrations were evaluated at baseline, after 4\u2009days of treatment (D4) and 1\u2009day after the last treatment (D8). Data were analyzed using linear mixed models with Benjamini‐Hochberg adjustments. Results Lung resistance significantly improved at D4 (mean decrease ± SD, −1.5\u2009±\u20090.45\u2009cm H₂O/L/s; 95% confidence interval [CI], −2; −0.6) and D8 (−1.4\u2009±\u20090.45\u2009cm H₂O/L/s; 95% CI, −2.4; −0.5) compared to baseline in the OR group only (P = .004 and .01, respectively). Serum cortisol concentration was significantly decreased at D4 and D8 for both groups (maximum decrease, −1.2\u2009±\u20090.3 μg/dL; 95% CI, −1.9; −0.6 at D4 for NE group and\u2009−2.2\u2009±\u20090.3 μg/dL; 95% CI, −2.8; −1.6 at D8 for OR group; P\u2009<\u2009.001). Conclusions and Clinical Importance Oral, but not nebulized dexamethasone is an effective therapy for horses with severe asthma and both treatment modalities inhibit the hypothalamic‐pituitary‐adrenal axis.